Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2

By Hillgenberg M.   Schlehofer J.R.   von Knebel Doeberitz M.   Klein-Bauernschmitt P.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 106-110

Elsevier

Access to resources Recommend Favorite

Vinorelbine, Ifosfamide and Cisplatin in Advanced Non-Small Cell Lung Cancer

By Tan Eng-Huat   Ang Peng Tiam   Wee Joseph   Fong Kam Weng   Leong Swan Swan   Khoo Kei Siong  

Acta Oncologica, Vol. 38, Iss. 5, 1999-06 ,pp. : 619-622

Informa Healthcare

Access to resources Recommend Favorite

Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer

By Kroep J.   Smit E.   Giaccone G.   Born K.   Beijnen J.   Groeningen C.   Vijgh W.   Postmus P.   Pinedo H.   Peters G.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 509-516

Springer Publishing Company

Access to resources Recommend Favorite

Clinical significance of expanded Foxp3+ Helios- regulatory T cells in patients with non-small cell lung cancer

By                            

International Journal of Oncology, Vol. 47, Iss. 6, 2015-01 ,pp. : 2082-2090

Spandidos Publications

Access to resources Recommend Favorite

Paclitaxel, cisplatin, etoposide combination chemotherapy: a multifractionated bolus dose schedule for non-small cell lung cancer

By Lokich J.   Anderson N.   Bern M.   Coco F.   Gotthardt S.   Oliynyk P.   Dow E.  

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 659-663

Elsevier

Access to resources Recommend Favorite